These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15918234)

  • 1. Atazanavir affects saquinavir.
    AIDS Patient Care STDS; 2005 Apr; 19(4):273-4. PubMed ID: 15918234
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
    Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
    Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atazanavir: clinical use.
    Bartlett JG
    Hopkins HIV Rep; 2003 Jul; 15(4):3-4. PubMed ID: 14696561
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 6. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
    [No Abstract]   [Full Text] [Related]  

  • 7. Interaction between cat's claw and protease inhibitors atazanavir, ritonavir and saquinavir.
    López Galera RM; Ribera Pascuet E; Esteban Mur JI; Montoro Ronsano JB; Juárez Giménez JC
    Eur J Clin Pharmacol; 2008 Dec; 64(12):1235-6. PubMed ID: 18712519
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.
    von Hentig N; Lötsch J
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3524-7. PubMed ID: 19528289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An unusual case of HIV virologic failure during treatment with boosted atazanavir.
    Duncan A; Mills J
    AIDS; 2013 May; 27(8):1361-2. PubMed ID: 23925384
    [No Abstract]   [Full Text] [Related]  

  • 11. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
    Vrouenraets SM; Wit FW; Fernandez Garcia E; Moyle GJ; Jackson AG; Allavena C; Raffi F; Jayaweera DT; Mauss S; Katlama C; Fisher M; Slama L; Hardy WD; Dejesus E; van Eeden A; Reiss P;
    HIV Med; 2011 Nov; 12(10):620-31. PubMed ID: 21819530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug profile: atazanavir (Reyataz, ATV).
    Pham PA
    Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
    [No Abstract]   [Full Text] [Related]  

  • 13. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
    Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
    AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing dosing strategies for the combination of atazanavir plus saquinavir.
    Schutz M; Sargent S; Kakuda T
    AIDS; 2004 Mar; 18(4):704-5. PubMed ID: 15090782
    [No Abstract]   [Full Text] [Related]  

  • 16. Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
    Med Lett Drugs Ther; 2003 Nov; 45(1169):90-2. PubMed ID: 14603099
    [No Abstract]   [Full Text] [Related]  

  • 17. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
    [No Abstract]   [Full Text] [Related]  

  • 19. Atazanavir: the advent of a new generation of more convenient protease inhibitors.
    Barreiro P; Rendón A; Rodríguez-Nóvoa S; Soriano V
    HIV Clin Trials; 2005; 6(1):50-61. PubMed ID: 15765311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of saquinavir in children during long term treatment.
    Grub S; Schwarzwald HL; Kline MW; Jorga K
    Pediatr Infect Dis J; 2002 Jul; 21(7):712-3. PubMed ID: 12237613
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.